anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Pulmonary fibrosis (PF) is a progressive lung disorder with a poor prognosis. GBE50 is a new standardized Ginkgo biloba extract that has been widely used in cardiovascular diseases. However, the protective mechanism of GBE50 against PF remains to be elucidated.
METHODS: C57BL/6J mice were treated with bleomycin (Bleo) to induce PF in the presence or absence of GBE50. Protein content in bronchoalveolar lavage fluid (BALF) and wet weight/dry weight ratio were examined for analysis of pulmonary edema. Hematoxylin-eosin staining and Masson trichrome staining were used for histopathological observation of murine lung tissues. Ashcroft score was used for semi-quantitation of lung fibrosis degree. RT-qPCR was utilized for assessing mRNA levels of pro-fibrotic mediators in lung tissues. TUNEL staining was implemented for cell apoptosis assessment. The levels of oxidative stress- and inflammation-related markers were evaluated by corresponding commercial assay kits. Western blotting was used to evaluate levels of nuclear factor erythroid 2-related factor 2 (Nrf2) signaling- and transforming growth factor (TGF)-β1/SMAD signaling-related proteins.
RESULTS: GBE50 alleviated lung injury and severity of fibrosis, reduced collagen deposition and cell apoptosis in lung tissues, and suppressed inflammatory response and oxidative stress injury in Bleo-stimulated PF mice. GBE50 activated Nrf2 signaling pathway and inactivated TGF-β1/SMAD signaling pathway in the lungs of Bleo-induced PF mice. Inhibition of Nrf2 signaling reversed GBE50-mediated inactivation of TGF-β1/SMAD signaling and attenuation of inflammation and oxidative stress in Bleo-induced PF mice.
CONCLUSION: GBE50 protects against Bleo-induced PF in mice by mitigating fibrosis, inflammation and oxidative stress via Nrf2 and TGF-β1/SMAD signaling pathways.
This study will recruit 20 subjects with multiple sclerosis (MS) to participate in a 6-week yoga/meditation program. Subjects will be randomly assigned to one of two groups. The first group will complete the yoga/meditation classes, followed by a waiting period. The second group will go through a waiting period, followed by yoga/meditation classes. Two subjects assigned to classes during the first session will be selected to participate in an MRI sub-study to look for biomarkers of MS-associated fatigue. All subjects will complete questionnaires and assessments during 3 clinic visits - at baseline, in between the class sessions, and at the end of the study. Questionnaires will also be mailed to subjects 6 weeks after the last study visit.
Peripheral artery disease is characterized by reduced exercise capacity, physical activity level and intermittent claudication. The number of studies investigating maximal and submaximal exercise capacity and physical activity level in PAD is limited. There is also no study investigated pulmonary functions, respiratory muscle strength and endurance in this patient population. According to the sample size analysis 15 patients and 15 healthy individuals with similar demographic characteristics will be included the study. Patients and healthy individuals will be selected according to predetermined inclusion and exclusion criteria. The assessments will be completed in two days.Maximal exercise capacity will be assessed using cardiopulmonary exercise testing (CPET), functional exercise capacity using six minute stepper test, physical activity using multi-sensor activity monitor, pulmonary function using spirometry, respiratory muscle strength using mouth pressure device, peripheral muscle strength using hand held dynamometer, respiratory muscle endurance using incremental threshold loading test, depression using Beck depression inventory (Turkish version), life quality using SF-36 Health Survey (Turkish version), intermittent claudication using Walking Impairment Questionnaire (Turkish version)
PURPOSE:To retrieve efficiently a desired picture data in a short time by retrieving a picture data corresponding to a retrieved key word of the inputted desired picture data with priority from the retrieved data to a picture data having a high access frequency. CONSTITUTION:A retrieved key word of a desired picture data is inputted from a keyboard 15 and a retrieval device 16 retrieves the retrieval data corresponding to the retrieval key work out of the retrieved data stored in a priority retrieval data file section 14 with priority for frequency. When there is a retrieval data, a corresponding picture data is extracted from a picture data file 12 and access number of times is incremented. When no retrieval data exists, the data in a retrieval data file section 13 is retrieved. When any corresponding retrieval data exists, the corresponding picture data is extracted and the access number is incremented. The access number and the minimum access number of the picture data in the file section 14 are compared and when the latter is small, the corresponding retrieval data is erased from the file 14 and the accessed retrieval data is stored to there.
The utility model refers to a cosmetic product used in the cosmetics and / or pharmaceutical industry for the production of creams, gels, lotions intended for treatment of the skin. According to the utility model, a cosmetic composition is created, which contains: animal oil from 5.0 to 11.5, vegetable oil from 0.5 to 10, fatty acids from 0.1-5.0, animal waxy substances from 0.5 to 5.0; fat-soluble vitamins from 0.1 to 2.0, rose water from 40 to 65, liquid paraffin from 20 to 40 and borax from 0.5 to 1.0. An advantage of the cosmetic composition according to the present utility model is that the described cosmetic product according to the present utility model contains substances qualitatively, quantitatively selected in such proportions so that they provide the desired effect. The cosmetic composition is equally well absorbed by normal, dry, oily and problem skins. It has a soothing effect on problem skins. Protects the skin from the harmful effects of the environment. The correct combination and balance of fats and fatty acids is extremely important for the restoration and maintenance of the water-lipid balance of the skin, as well as the nourishment of the treated skin. The coenzyme Q10 included in the composition protects the skin from free radicals and regenerates it, not only on the surface but also in depth. It retains moisture, maintains skin elasticity to a high enough degree. It generally supports the healing processes of skin problems, soothes the skin and has a regenerating effect. The inclusion of rose water tones and softens the skin further. The pure bee product used does not allow the penetration of microorganisms of any kind. The cosmetic product performs the function of simultaneous preservation, protection and enrichment of the skin. The cosmetic product, according to the current utility model, does not replace, but restores the natural functions of the skin: respiration, removal of toxins. regeneration, protection and preserves its natural balance.
Ischemic stroke remains a leading cause of death and long-term disability worldwide,1 despite major advancements in reperfusion therapies.2,3 While neuroimaging modalities have expanded patient eligibility for reperfusion therapies by estimating ischemic core and salvageable tissue,4-7 their assessments are mostly single-timed. Currently available clinical algorithms lack the capacity to continuously track the dynamic evolution of how the primary core progresses to a final infarct, which, however, is a major determinant of functional outcome.8-10 Monitoring infarct trajectories could support therapeutic decision-making in patients with large-vessel occlusion stroke and unveil determinants of stroke progression, aiding in patient selection for trials evaluating cytoprotection11 and targeting clinically ineffective reperfusion.12 Previously studied blood-based biomarkers such as Neurofilament Light Chain (NfL),13 neuron-specific enolase (NSE),14 glial fibrillary acidic protein (GFAP),15,16 and S 100 calcium-binding protein B (S100B)17 either failed to capture the extent of brain injury within the acute phase of stroke or lack specificity. Plasma levels of brain-derived tau (BD-tau) were recently found to show high value for monitoring brain injury in patients with acute ischemic stroke: In 502 patients with acute IS, plasma BD-tau was associated with imaging-based metrics of brain injury upon admission, increased within the first 24 hours in correlation with infarct progression, and at 24 hours was superior to final infarct volume in predicting 90-day functional outcome.18 While informing on the relation of BD-tau with imaging-based metrics of brain injury, this large cross-sectional study was restricted to BD-tau assessments upon admission (median time from onset: 4.4 hours) and at day 2 (median time from onset: 22.7 hours) and could not inform on key characteristics of the evolution of plasma BD-tau, including when exactly it starts to rise, how long it continues to rise, and how it is determined by infarct characteristics as well as comorbidities. That knowledge would be of great value to determine the responsiveness of plasma BD-tau to brain injury after onset and to evaluate whether BD-tau plateaus at different time points after onset indicating no further infarct progression. Here, the investigators hypothesize that BD-tau rises immediately after onset and plateaus between three and 48 hours after onset. PROMISE-BD-100 will thus assess BD-tau levels every hour from admission to 48 hours from stroke onset in patients that present with the clinical diagnosis of an acute ischemic stroke due to a large- or medium-vessel occlusion within 9 hours from symptom onset.
High-resolution manometry (HRM) is the gold standard for diagnosing esophageal motility disorders, yet it can be poorly tolerated and technically challenging. Epiphrenic diverticula (ED) are located in the distal esophagus and are associated with underlying motility disorders. ED patients (2008-2022) were retrospectively compared to achalasia patients (2008-2022) and all other patients (2021-2022) who underwent HRM at a single center. Complete success was defined as at least 7 interpretable swallows including measurements throughout the esophagus into the stomach. HRM studies involving children, previously treated achalasia, and sedation or endoscopic-assistance were excluded. 20 ED patients (mean age 66; 60% female) were compared to 76 achalasia patients and 199 controls. HRM was completely successful in 70.0% of ED patients, 85.5% of achalasia (p = 0.106 vs ED), and 91.0% of controls (p = 0.004 vs ED). Most failures in the ED and achalasia groups were due to inability to traverse the esophagogastric junction (EGJ), while patient intolerance was the main reason in controls. Half of the ED group had motility disorders (25% achalasia, 15% hypercontractile esophagus, 10% absent contractility). Large diverticulum size was inversely associated with technical success compared to small diverticulum size (40% vs 100%, p = 0.013), while the presence of a motility disorder did not significantly affect success (60% vs 88.9%, p = 0.303). In conclusion, ED is a predictor of unsuccessful HRM. This appears to be mainly related to an inability to traverse the EGJ due to the size of the diverticulum. Consideration should be given to alternative means of evaluating motility, such as endoscopy-assisted HRM, given the high likelihood of failure with traditional HRM.
Cancer rehabilitation interventions that address common impairments and focus on maintaining or reducing the rate of functional decline are greatly needed for the growing population of cancer survivors living with incurable or metastatic cancer. In the curative setting, the main gaps in care include lack of referral and barriers to access care; however, in the metastatic setting, high quality evidence on safety, acceptability, and efficacy is still required. In response, based on the results of a need assessments (n=50) of this population and input from palliative care experts, we recently developed the CaRE-Advanced Cancer (CaRE-AC) program. Similar to CaRE@ELLICSR, CaRE-AC is an 8-week multidimensional, group-based program with exercises classes and selfmanagement skills teaching. A single-arm phase I pilot of this program is currently being conducted to assess the feasibility and acceptability (Co-PIs Jones/Langelier). To date, 14 patients have enrolled and 9 patients have completed the program (64%). All participants reported feeling the program was safe and 90% were satisfied with the structure and content.

Data collection is expected to be complete be the end of 2019 and the findings will inform revisions to the program format and content. To build on this work, Project Three is a Phase II feasibility RCT of the CaRE-AC program. Results will inform the development of a multicentre pragmatic RCT protocol.
The invention relates to the creation of mechanically activated amorphous and amorphocrystalline compounds and compositions of a gluconic acid calcium salt, pharmaceutical preparations based thereon, a method for producing same and use for treatment of a wide range of diseases caused by disorders of calcium metabolism in an organism. A concept of the invention, as being claimed and as set forth in the application, consists in that the crystalline gluconic acid calcium salt or its compound with excipients is treated in grinding activator devices either up to the input specific energy value of not greater than 10.4 kJ/g and achieving an amorphocrystalline state or up to the input specific energy value of no less than 10.5 kJ/g and achieving an amorphous state. The obtainable agents are assessed by means of X-ray diffraction, IR, NMR, EPR spectroscopy, mass- or chromato-mass-spectrometry, and a differential thermal analysis. The mechanically activated amorphous and amorphocrystalline compounds and compositions are used as an active principle for preparing pharmaceutical preparations used for therapeutic, therapeutic-preventive and hygienic purposes. The pharmaceutical preparations comprising a therapeutically effective amount of active ingredient are used perorally 1-6 times daily, in dosages of 0.2-6 g, a course of at least 1 month. The invention can be used in medical and food industries in the production of biologically active agents, therapeutic-prophylactic means, medicinals and in practical medicine in treatment of acute osseous, dental and other diseases related to disorders of calcium metabolism in the organism.
A skin cleansing composition is provided that includes a combination of C16?-C18? acyl isethionate ester salts having no more than 25 % C14? or lower acyl groups with at least one co-active surfactant. The weight ratio of acyl isethionate to co-active will range from about 20:1 to about 1:1. Soap is present in an amount no higher than 10 % by weight of the composition. The compositions are mild and in bar form can have improved lather and mush properties.
PURPOSE:To produce and collect human immunoglobulin efficiently on the outside of a body, by utilizing a hybridized cellular clone of two human B-cells having different abilities to produce the immunoglobulin. CONSTITUTION:(A) A human B-cell having the ability to produce immunoglobulin, e.g. B-cell of human lymphocytes sensitized by a pathogenic antigen, is brought into contact with (B) a human B-cell, having substantially no ability to produce the immunoglobulin, and capable of self-multiplying and stopping the multiplication (or dying) in the presence of a specific reagent, e.g. in the presence of a plasmogamy accelerator, e.g. Sendai virus or polyethylene glycol, to produce the aimed hybridized cell (hybridoma) between the (A) the human B-cell and (B) the human B-cell. The resultant hybridized cell is then cultivated in a culture medium stopping the multiplication (or exterminating) the human B-cells (A) and (B), and the resultant immunoglobulin having the same character as that of (A) the above-mentioned B-cell is collected from the resultant hybridized cellular clone.
Participants in the experimental group will be given foot care in the clinic and will be taught to the patient and / or their relatives. The foot care video will be uploaded to the patient and / or relative's phone. Thermal evaluation will be done. The application of the thermal evaluation, the foot areas to be applied and how to record the results of the application will be taught to the patient and / or their relatives. In addition, the thermal evaluation video will be uploaded to the phone of the patient and / or their relative. While the participants in the experimental group were discharged; Blood glucose monitoring chart, Checklist to record foot care interventions, Thermal evaluation registration form, Daily step number registration form will be provided and participants will be invited to check every 2 months.
Disclosed is a liquid stream comprising a plurality of solid, polymeric microparticles. The microparticles are suspended in a liquid with a flow rate of between 0.8 and 5 cm3/s. The microparticles are present at a density of between 100000 and 750000 microparticles/cm3. Preferably the microparticles encapsulate a target material which comprises a pharmaceutically active agent. The microparticles may encapsulate a target material which comprises a plurality of nanoparticles. Preferably the stream of microparticles may comprise a jet, more preferably the jet is not in contact with any wall or channel for at least part of its length. The solid polymeric microparticles may comprise a biocompatible polymer, preferably one of polylactide, polyglycolide, polycaprolactone, and a copolymer of lactic acid and glycolic acid (PLGA), more preferably this polymer comprises PLGA.
IMPORTANCE: National implementation of rapid trio genome sequencing (rtGS) in a clinical acute setting is essential to ensure advanced and equitable care for ill neonates.
OBJECTIVE: To evaluate the feasibility, diagnostic efficacy, and clinical utility of rtGS in neonatal intensive care units (NICUs) throughout Israel.
DESIGN, SETTING, AND PARTICIPANTS: This prospective, public health care-based, multicenter cohort study was conducted from October 2021 to December 2022 with the Community Genetics Department of the Israeli Ministry of Health and all Israeli medical genetics institutes (n = 18) and NICUs (n = 25). Critically ill neonates suspected of having a genetic etiology were offered rtGS. All sequencing, analysis, and interpretation of data were performed in a central genomics center at Tel-Aviv Sourasky Medical Center. Rapid results were expected within 10 days. A secondary analysis report, issued within 60 days, focused mainly on cases with negative rapid results and actionable secondary findings. Pathogenic, likely pathogenic, and highly suspected variants of unknown significance (VUS) were reported.
MAIN OUTCOMES AND MEASURES: Diagnostic rate, including highly suspected disease-causing VUS, and turnaround time for rapid results. Clinical utility was assessed via questionnaires circulated to treating neonatologists.
RESULTS: A total of 130 neonates across Israel (70 [54%] male; 60 [46%] female) met inclusion criteria and were recruited. Mean (SD) age at enrollment was 12 (13) days. Mean (SD) turnaround time for rapid report was 7 (3) days. Diagnostic efficacy was 50% (65 of 130) for disease-causing variants, 11% (14 of 130) for VUS suspected to be causative, and 1 novel gene candidate (1%). Disease-causing variants included 12 chromosomal and 52 monogenic disorders as well as 1 neonate with uniparental disomy. Overall, the response rate for clinical utility questionnaires was 82% (107 of 130). Among respondents, genomic testing led to a change in medical management for 24 neonates (22%). Results led to immediate precision medicine for 6 of 65 diagnosed infants (9%), an additional 2 (3%) received palliative care, and 2 (3%) were transferred to nursing homes.
CONCLUSIONS AND RELEVANCE: In this national cohort study, rtGS in critically ill neonates was feasible and diagnostically beneficial in a public health care setting. This study is a prerequisite for implementation of rtGS for ill neonates into routine care and may aid in design of similar studies in other public health care systems.
The GH treatment arm will receive a starting dose of 400 microgramsg/day, with increases (or decreases) in dose by 100-200 micrograms/day each month, monitoring for side effects, until goal IGF-1 (in the upper quartile of the range for age and body weight) is reached up to maximum dose of 1,000 microgramsg/day. Dose adjustments may be modified by the investigators for participants receiving oral estrogens or other circumstances know to influence GH dosing or atypical responses to treatment.
The neurodevelopmental effect of antipsychotics on fetus has always been a major concern for women who need antipsychotic treatments and are in their reproductive years. The fear of harmful effects from antipsychotic on fetus and unplanned pregnancy commonly causes non-adherence to treatments. Even for those who are willing to maintain their antipsychotic treatments during pregnancy, the fear of potential harmful effects from antipsychotic on fetus can still exist. It is well known that non-adherence to antipsychotic treatments in patients with schizophrenia can cause most to relapse and poor treatment response. The consequences of relapse not only increase personal suffering, but also increase family and societal burden.Clearly, it is important to evaluate the safety of antipsychotics during pregnancy. However, up to now, most information about antipsychotics on reproductive safety and the effects on infant development come from case reports, case series, and retrospective studies.So the study was to investigate the developmental effects of antipsychotics on infants who were exposed to as fetus.
BACKGROUND: Acute upper gastrointestinal bleeding (UGIB) is a common emergency requiring hospital-based care. Advances in care across pre-endoscopic, endoscopic and post-endoscopic phases have led to improvements in clinical outcomes.
AIMS: To provide a detailed, evidence-based update on major aspects of care across pre-endoscopic, endoscopic and post-endoscopic phases.
METHODS: We performed a structured bibliographic database search for each topic. If a recent high-quality meta-analysis was not available, we performed a meta-analysis with random effects methods and odds ratios with 95% confidence intervals.
RESULTS: Pre-endoscopic management of UGIB includes risk stratification, a restrictive red blood cell transfusion policy unless the patient has cardiovascular disease, and pharmacologic therapy with erythromycin and a proton pump inhibitor. Patients with cirrhosis should be treated with prophylactic antibiotics and vasoactive medications. Tranexamic acid should not be used. Endoscopic management of UGIB depends on the aetiology. For peptic ulcer disease (PUD) with high-risk stigmata, endoscopic therapy, including over-the-scope clips (OTSCs) and TC-325 powder spray, should be performed. For variceal bleeding, treatment should be customised by severity and anatomic location. Post-endoscopic management includes early enteral feeding for all UGIB patients. For high-risk PUD, PPI should be continued for 72 h, and rebleeding should initially be evaluated with a repeat endoscopy. For variceal bleeding, high-risk patients or those with further bleeding, a transjugular intrahepatic portosystemic shunt can be considered.
CONCLUSIONS: Management of acute UGIB should include treatment plans for pre-endoscopic, endoscopic and post-endoscopic phases of care, and customise treatment decisions based on aetiology and severity of bleeding.